Analysts predict that Genocea Biosciences Inc (NASDAQ:GNCA) will post ($0.41) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.36). Genocea Biosciences posted earnings per share of ($0.88) in the same quarter last year, which would indicate a positive year over year growth rate of 53.4%. The company is scheduled to issue its next quarterly earnings results on Thursday, February 27th.
According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.13) to ($1.91). For the next fiscal year, analysts forecast that the business will report earnings of ($1.60) per share, with EPS estimates ranging from ($1.87) to ($1.12). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, October 24th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.17.
A number of research analysts have commented on GNCA shares. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Genocea Biosciences in a research note on Thursday, October 24th. ValuEngine cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Genocea Biosciences in a research note on Monday, November 11th. Svb Leerink began coverage on Genocea Biosciences in a report on Friday, November 15th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Leerink Swann assumed coverage on Genocea Biosciences in a research report on Friday, November 15th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $12.94.
NASDAQ:GNCA traded down $0.12 during trading hours on Thursday, reaching $2.30. 655 shares of the company’s stock were exchanged, compared to its average volume of 146,535. Genocea Biosciences has a 1-year low of $1.99 and a 1-year high of $11.28. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $65.37 million, a price-to-earnings ratio of -0.63 and a beta of 2.42. The company has a 50-day moving average of $2.42 and a 200 day moving average of $3.30.
Several hedge funds and other institutional investors have recently modified their holdings of GNCA. FNY Investment Advisers LLC acquired a new position in shares of Genocea Biosciences during the second quarter worth about $526,000. Wedbush Securities Inc. acquired a new position in Genocea Biosciences during the 2nd quarter worth approximately $43,000. Wells Fargo & Company MN increased its position in Genocea Biosciences by 271.9% during the 2nd quarter. Wells Fargo & Company MN now owns 33,631 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 24,587 shares during the period. Monashee Investment Management LLC purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $392,000. Finally, DRW Securities LLC purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $118,000. 52.89% of the stock is owned by hedge funds and other institutional investors.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Article: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.